Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People with HIV are at greater risk for hepatitis B but are less likely to get vaccinated and respond to vaccines.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
Antiretroviral therapy for HIV, also effective against HBV, lowers the risk of developing chronic hepatitis.
Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.
Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
The Trump administration had proposed changing which meds were covered, including HIV and cancer drugs.
Regardless of whether individuals have hepatitis B or C, the improvement tends to occur quickly.
HIV-positive people have a much higher risk of certain cancers. Here are some ways to help improve your chances of avoiding cancer.
The HIV antiretroviral Viread (tenofovir) is highly effective in combating both HIV and hepatitis B among those coinfected with both viruses
Many deaths in people with HIV are now preventable?if people are able to not only control HIV, but also make lifestyle changes.
New guidelines from the U.S. Department of Health and Human Services recommend starting HIV meds even earlier than before—but the...
Antiretroviral (ARV) therapy is now recommended for certain people living with HIV with CD4 counts between 350 and 500 cells, according to..
Being infected with the hepatitis C virus (HCV) doesn’t prevent people with HIV from experiencing increases in CD4 cells after starting...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.